Silk Road Medical upgraded to Buy from Hold at Stifel

Stifel upgraded Silk Road Medical to Buy from Hold with a price target of $20, up from $9. The company’s newly appointed CEO McKhann spoke publicly at a major competitor healthcare conference last week, articulating that Silk Road Medical’s compelling vision for getting back on track remains intact, the analyst tells investors in a research note. McKhann’s comments directly addressed and answered most of the concerns and uncertainties that led to the firm’s downgrade in October, Stifel stated, adding that the CEO’s utilization-focused commercial initiatives set the stage for better and more consistent growth in 2024 and beyond.